ATAI arrives at Thursday's print carrying one of the most pronounced divergences in its positioning data — short sellers have largely walked away, while the analyst community has spent the past month walking out.
The short-side retreat is the most dramatic development in the data since the previous article. Short interest has collapsed nearly 48% over the past month, now at 8.2% of the free float after a 37% single-session drop on August 11. Borrow availability has flipped from tight — running below 150% through most of July — to essentially unconstrained, now at 999%, with cost to borrow a negligible 0.55%. The ORTEX short score fell sharply to 40.4, down from readings near 49 for most of the prior week. Whatever drove bears to press heavily through early July, they have since largely stood down.
The analyst picture moves in the opposite direction. The past four weeks produced one of the most coordinated downgrade waves AtaiBeckley has seen — six firms moved from Buy to Hold or Neutral in a single week in mid-July, followed by Deutsche Bank downgrading to Hold and cutting its target from $12 to $8 on August 12. The consensus now sits at Hold, with two Buy ratings against twelve Holds and a mean price target of $9.09. That target still implies roughly 25% upside from the current $7.23, but the direction of travel is unambiguously negative: HC Wainwright cut its target from $25 to $7.50, and Jefferies trimmed from $10 to $7.50. The Street is not abandoning the story, but it is materially lowering expectations.
What bulls and bears actually disagree about is the Eli Lilly partnership. The $2.8 billion deal validates AtaiBeckley's mental health pipeline — particularly the VLS-01 programme — and the stock has gained 40% over the past month. Bulls point to the deal as durable evidence that large pharma sees value in the TRD space, and the company's 77% year-to-date gain reflects that confidence. Bears counter that the VLS-01 probability of success has been revised down following updated clinical data, that the treatment model faces real cost and durability questions, and that the recent premium leaves little room for disappointment. BlackRock added 18.7 million shares as of July 31, a notable institutional vote of confidence that partly offsets the analyst caution — but the insider register is net sellers over the past 90 days, with the COO, CMO, and a director all trimming in June and July.
Thursday's print is therefore less a test of whether the Lilly deal happened and more a question of what AtaiBeckley can demonstrate about clinical progress and cash runway — the two variables the downgrading analysts appear least convinced by.
See the live data behind this article on ORTEX.
Open ATAI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
